| Description | The enzyme is useful for the determination of α-amylase and inorganic phosphate in clinical analysis.PROPERTIESMolecular weight: ca. 34 kDa (gel filtration)Structure: monomer of ca. 25 kDa (SDS-PAGE)Michaelis constant: 2.3×10^−4 M (β-d-glucose-1-phosphate)pH Optimum: ca. 7.0 (The enzyme is useful for the determination of α-amylase and inorganic phosphate in clinical analysis.PROPERTIESMolecular weight: ca. 34 kDa (gel filtration)Structure: monomer of ca. 25 kDa (SDS-PAGE)Michaelis constant: 2.3×10^−4 M (β-d-glucose-1-phosphate)pH Optimum: ca. 7.0 (Fig. 1)pH Stability: 5.0–9.5 (Fig. 2)Optimum temperature: 40°C (Fig. 3)Thermal stability: below 45°C (Fig. 4)Stability (liquid form): stable at 37°C for at least one week (Fig. 5)Stability (powder form): stable at 30°C for at lest one month (Fig. 6)Activators: Mg2+, Mn2+, Co2+, Ni2+Inhibitors: Hg2+, Zn2+, Cu2+, Cd2+STABILIZERS: lactose, EDTAASSAY PROCEDURE PrincipleThe appearance of NADPH is measured spectrophotometrically at 340 nm.ReagentsA. HEPES–NaOH buffer, 0.3 M; pH 7.0, containing 40 mM KCl, 4 mM MgCl2 and 1.6% (w/v) Triton X-100: dissolve 7.15 g of HEPES, 298 mg of KCl, 81.3 mg of MgCl2·6H2O and 1.6 g of Triton X-100 in 75 ml of distilled water, adjust to pH 7.0 with 4 N NaOH and dilute with distilled water to 100 ml.B. d-Glucose-1,6-bisphosphate (G-1,6-P2) solution, 3.0 mM : 60.7 mg of G-1,6-P2 cyclohexylammonium·4H2O/ 25 ml of distilled water.C. NADP+ solution, 12 mM: 230 mg of NADP+·Na/25 ml of distilled water.D. β-d-Glucose-1-phosphate (β-G-1-P) solution, 22 mM:167 mg of β-G-1-P disodium salt/25 ml of distilled water.E. Glucose-6-phosphate dehydrogenase (G6PDH) solution: 1750 U/ml.F. Enzyme dilution buffer: mix 10 mM KH2PO4 solution and 10 mM K2HPO4 solution to make a pH 7.0 solution.Sample: dissolve the lyophilized enzyme to a volume activity of 1.0–3.0 U/ml with ice-cold enzyme dilution buffer (Reagent F) immediately before measurement. Procedure1. Pipette the following reagents into a cuvette (light path: 1 cm).1.5 ml HEPES–NaOH buffer (Reagent A)0.3 ml G-1,6-P2 solution (Reagent B)0.3 ml NADP+ solution (Reagent C)0.3 ml β-G-1-P solution (Reagent D) 0.02 ml G6PDH solution (Reagent E)0.6 ml Distilled water2. Equilibrate at 37°C for about 5 min.3. Add 0.03 ml of sample and mix.4. Record the increase of absorbance at 340 nm in a spectrophotometer thermostated at 37°C, and calculate the ∆Aper min using the linear portion of the curve (∆AS).The blank solution is prepared by adding enzyme dilution buffer (Reagent F) instead of sample (∆A0).CalculationActivity can be calculated by using the following formula:6.2: Millimolar extinction coefficient of NADPH at 340 nm (cm2/µmol)df: Dilution factorC: Content of β-phosphoglucomutase preparation in sample (mg/ml)APPLICATIONSThe enzyme is useful for the determination of α-amylase and inorganic phosphate in clinical analysis.EXPERIMENTAL DATA... Read More | Purity> 96% by SDS-PAGE and HPLC analyses.FunctionHas weak activities on human monocytes and acts via receptors that also recognize MIP-1 alpha. It induced intracellular Ca(2+) changes and enzyme release, but no chemotaxis, at concentrations of 100-1,000 nM, and was inactive on T-lymphocytes, Purity> 96% by SDS-PAGE and HPLC analyses.FunctionHas weak activities on human monocytes and acts via receptors that also recognize MIP-1 alpha. It induced intracellular Ca(2+) changes and enzyme release, but no chemotaxis, at concentrations of 100-1,000 nM, and was inactive on T-lymphocytes, neutrophils, and eosinophil leukocytes. Enhances the proliferation of CD34 myeloid progenitor cells. The processed form HCC-1(9-74) is a chemotactic factor that attracts monocytes eosinophils, and T-cells and is a ligand for CCR1, CCR3 and CCR5.Post-translationalThe N-terminal processed forms HCC-1(3-74), HCC-1(4-74) and HCC-1(9-74) are produced in small amounts by proteolytic cleavage after secretion in blood. HCC-1(1-74), but not HCC-1(3-74) and HCC-1(4-74), is partially O-glycosylated; the O-linked glycan consists of one Gal-GalNAc disaccharide, further modified by two N-acetylneuraminic acids... Read More | Purity:>95%, by SDS-PAGE visualized with Coomassie® Blue Staining.Description：CD200 R1, also known as OX-2 receptor, is a 90 kDa transmembrane protein in the immunoglobulin superfamily and is important in the regulation of myeloid cell activity. The human CD200 R1 cDNA encodes a 325 Purity:>95%, by SDS-PAGE visualized with Coomassie® Blue Staining.Description：CD200 R1, also known as OX-2 receptor, is a 90 kDa transmembrane protein in the immunoglobulin superfamily and is important in the regulation of myeloid cell activity. The human CD200 R1 cDNA encodes a 325 amino acid (aa) precursor that includes a 28 aa signal sequence, a 215 aa extracellular domain (ECD), a 21 aa transmembrane segment, and a 61 aa cytoplasmic domain. The ECD is composed of one Ig-like V-type domain and one Ig-like C2-type domain. Within the ECD, human CD200 R1 shares 56% aa sequence identity with both mouse and rat CD200 R1. Alternate splicing of the human CD200 R1 mRNA generates four isoforms, two of which are truncated in the Ig-C2 domain and are likely secreted. In human, a separate CD200 RL gene encodes a protein that shares 81% ECD aa identity with CD200 R1. In mouse, at least four genes for CD200 R1-like molecules have been described. CD200 R1 expression is restricted primarily to mast cells, basophils, macrophages, and dendritic cells, while its ligand, CD200, is widely distributed. Disruption of this receptor-ligand system by knockout of the CD200 gene in mice leads to increased macrophage number and activation and predisposition to autoimmune disorders. Association of CD200 with CD200 R1 takes place between their respective N-terminal Ig-like domains. The capacity of CD200 R1-like molecules to interact with CD200 is controversial. CD200 R1 propagates inhibitory signals despite lacking a cytoplasmic ITIM (immunoreceptor tyrosine-based inhibitory motif). CD200 R1-like molecules, in contrast, are potentially activating receptors by means of their association with DAP12. CD200R1 signaling inhibits the expression of proinflammatory molecules including TNFs, IFNs, and inducible nitric oxide synthase in response to selected stimuli, which implicate that CD200/CD200R1 inhibitory signaling pathway plays a prominent role in limiting inflammation in a wide range of inflammatory diseases. Furthermore, the CD200/CD200R inhibitory signaling constitutes one of the most suitable endogenous immunoregulatory molecule candidate to restore the immune suppressive status of the CNS altered in chronic neuroinflammatory situations... Read More | Inquire | Inquire |